Form 4: Rapport Therapeutics Director Wendy Young Granted Stock Options

Rapport Therapeutics, Inc. Director Wendy B. Young was granted 10,925 stock options with an exercise price of $10.95, vesting based on continued service.

Summary

• Wendy B. Young, a Director of Rapport Therapeutics, Inc. (RAPP), reported the acquisition of derivative securities.
• The transaction occurred on June 17, 2025, involving the grant of 10,925 stock options.
• Each stock option has an exercise price of $10.95.
• The options are set to vest upon the earlier of June 17, 2026, or the date of the next Annual Meeting of Stockholders of the Issuer.
• Vesting is contingent upon Ms. Young's continued service as a director.
• The stock options have an expiration date of June 17, 2035.
• Following this transaction, Ms. Young beneficially owns 10,925 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While a Form 4 is primarily a disclosure of an insider transaction, the grant of options to a director is a positive signal as it aligns management/director interests with shareholders. It's a routine compensation event, not indicative of extraordinary news, hence not a 'strong buy' signal on its own.

Positives

• The grant of stock options to Director Wendy B. Young aligns her financial interests with those of the company's shareholders, incentivizing long-term value creation.
• This is a standard form of equity compensation for directors, reflecting ongoing commitment and engagement with the company's performance.

Risks

• The value of the stock options is subject to the future market price of Rapport Therapeutics, Inc. common stock, meaning the options may not be 'in the money' if the stock price does not exceed the exercise price of $10.95.
• Vesting of the options is subject to the reporting person's continued service, meaning the options could be forfeited if service ceases before the vesting date.

Future Outlook

The stock options are subject to a vesting schedule, with the earliest vesting date being June 17, 2026, or the date of the next Annual Meeting of Stockholders, contingent on the director's continued service. The options will expire on June 17, 2035.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industries, including for companies like Rapport Therapeutics, Inc. This form of compensation is widely used to attract and retain experienced board members and align their long-term interests with the company's strategic goals and shareholder value creation.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a standard practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The specific number of options (10,925) and the exercise price ($10.95) would typically be benchmarked against peer companies of similar market capitalization, stage of development, and industry sector, though no specific comparable companies or projects are mentioned in this filing.
• The vesting schedule (one year or next annual meeting, subject to continued service) is also a common structure for director equity grants, designed to ensure ongoing commitment.

Corporate Governance

Related Party Transactions

• The grant of stock options to Wendy B. Young, a Director of Rapport Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors. This is a standard and disclosed form of compensation.

Stakeholder Impact

• Shareholders: The grant of options aligns the director's incentives with shareholder interests, potentially leading to better long-term performance.
• Employees: While not directly impacting general employees, such compensation practices for leadership can set a precedent for performance-based incentives across the organization.

Next Steps

• The stock options will vest upon the earlier of June 17, 2026, or the date of the next Annual Meeting of Stockholders, subject to continued service.
• Upon vesting, the director will have the right to exercise the options to purchase common stock at the exercise price of $10.95 per share.
• The options will remain exercisable until their expiration date of June 17, 2035.

Key Dates

Keywords

Rapport Therapeutics, RAPP, SEC Form 4, Stock Option, Director Compensation, Equity Grant, Insider Transaction, Beneficial Ownership